CLOs on the Move

Bachem

www.bachem.com

 
Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.bachem.com
  • 3132 Kashiwa Street
    Torrance, CA USA 90505
  • Phone: 310.539.4171

Executives

Name Title Contact Details
Fariba Jashnian
 VP, Quality and Regulatory Affairs Profile

Similar Companies

Thrive Health Plans

Thrive Health Plans is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sensei Biotherapeutics

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.

Trellis Bioscience

Trellis Bioscience is a leader in identifying rare protective antibodies by screening human blood cells.

Groton Biosystems

Groton Biosystems is a Boxborough, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

PepGen

Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.